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A 59-year-old married male, a known case of line probe assay-confirmed multidrug-resistant pulmonary 
tuberculosis was treated with kanamycin, levofloxacin, ethionamide, ethambutol, pyrazinamide and cycloserine 
for seven months. He was responding to treatment, had gained five kg weight and underwent culture conversion. 
He presented with painful swelling of both the breasts for 15 days. It was not associated with nipple bleed-
ing or discharge. There was no history of any other drug intake. 3.5 cm and 3 cm single, tender, firm nodule 
concentric with nipple-areolar complex could be palpated in the right and left breasts, respectively (Figure 1). 
It was not associated with skin dimpling or nipple retraction. On examination, thyroid, external genitalia and 
secondary sexual characters were normal. Bilateral breast ultrasound revealed glandular tissue hyperplasia. 
Ultrasound of the abdomen and scrotum was normal. Liver and kidney function tests revealed no abnormality. 
His serum was non-reactive for HIV-1 and HIV-2 by ELISA. Serum TSH was 1.86 μIU/mL (0.3–5.5 μIU/mL), 
serum testosterone was 302.6 ng/dL (241–827 ng/dL), serum estradiol was 38.4 pg/mL (0–39.8 pg/mL). Computed 
tomography of the adrenals showed no abnormality. Ethionamide was suspected to be the cause of gyneco-
mastia and was stopped and replaced by para-aminosalicylic acid. His breast swelling resolved slowly within 
1 month after stopping ethionamide. Thus, a clinical diagnosis of ethionamide-induced gynecomastia was 
made. As per the World Health Organization (WHO) Uppsala monitoring center causality assessment scale [1], 
the present adverse reaction is probable/likely associated with ethionamide.
Gynecomastia is enlargement of male breast glandular tissue. Drugs are responsible for 10–25% of cases 
of gynecomastia. Drugs which are known to cause gynecomastia include spironolactone, ketoconazole, cimeti-
dine, estrogen preparations, 5-a reductase inhibitors, human chorionic gonadotropin, human growth hormone, 
gonadotropin releasing hormone (GnRH) analogs, risperidone, omeprazole, nifedipine, verapamil, efavirenz. 
Anti-tubercular drugs implicated to cause gynecomastia include isoniazid, ethionamide and thioacetazone 
[2–3]. Ethionamide is used for treatment of drug-resistant tuberculosis. The mechanism by which it causes 
gynecomastia is not known. PubMed search using MeSH terms “Ethionamide”, “Gynecomastia” revealed only 
two case reports (Table 1).
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Figure 1. Lateral view of enlarged right breast and enlarged left breast
Kunal Deokar et al., Gynecomastia in multidrug — resistant tuberculosis
163www.journals.viamedica.pl
Points which favor ethionamide-induced gynecomastia in our patient include: 1. Temporal association — 
recent onset of gynecomastia while the patient was taking anti-tuberculosis drugs; 2. Ethionamide is known 
to cause gynecomastia; 3. Exclusion of other causes: there was no history of any other drug intake. Normal 
biochemical and endocrinological investigations; 4. Dechallenge — gynecomastia disappeared after stopping 
ethionamide. Gynecomastia in our patient on the WHO Uppsala monitoring center causality assessment scale 
[3] is probable/likely associated with ethionamide.
Thus, our case report emphasizes the fact that ethionamide can cause painful gynecomastia and clinicians 
must be aware of this adverse event. In view of the frequent adverse events of second-line anti-tuberculosis 
drugs, implementation of pharmacovigilance and monitoring of adverse events (aDSM) have been recom-
mended by WHO.. Furthermore, a team approach to the management of adverse events known as Tuberculosis 
Consilium has shown to be useful [5].
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Table 1. Case reports of ethionamide- induced gynecomastia
Author Year Age of patient 
in years
Range of onset 
after starting 
suspected drug
De-challenge Re-challenge Sex hormones
Dixit et al. [3] 2012 38 2 months Yes Yes Normal
Sharma et al. [4] 2012 43 4 months Yes No Not done
Present case 2019 59 7 months Yes No Normal
